echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Merck's K-drug combination therapy for first-line treatment of esophageal cancer receives positive opinions from EU CHMP

    Merck's K-drug combination therapy for first-line treatment of esophageal cancer receives positive opinions from EU CHMP

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compile | river

    According to foreign media reports, Merck announced on May 24 that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of Merck’s anti-PD-1 therapeutic drug KEYTRUDA combined with platinum and fluorouracil.


    CHMP’s positive opinion is based on the results of the key Phase 3 KEYNOTE-590 trial.


    In this trial, KEYTRUDA combined 5-fluorouracil (5-FU) and cisplatin, compared with placebo combined 5-FU and cisplatin, regardless of histology or PD-L1 expression, overall survival and progression-free survival Significant improvement during the period.


    Reference source: Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.